Open Access

Hintergrund Die Zertifizierung von Zentren für Beatmungsentwöhnung in der neurologisch-neurochirurgischen Frührehabilitation (NNFR) durch die Deutsche Gesellschaft für Neurorehabilitation (DGNR) ist seit dem 01.10.2021 möglich. Ziel der Arbeit Die Ergebnisse der Zertifizierung von Einrichtungen im ersten Jahr nach Aufnahme des Verfahrens werden vorgestellt. Material und Methoden Im Rahmen der Zertifizierung werden 28 Kriterien geprüft, darunter eine Reihe mandatorisch zu erfüllender Charakteristika der Einrichtung. Die Kriterien gliedern sich in Strukturkriterien (i = 7), Diagnostikkriterien (i = 6), Personalkriterien (i = 3), Kriterien der internen Organisation (i = 7) und Qualitätsmanagementkriterien (i = 5). Ergebnisse Insgesamt 13 Zentren wurden im ersten Jahr zertifiziert, die zusammen über 283 Betten zur Beatmungsentwöhnung („weaning“) in der NNFR verfügen und im Jahr vor der Zertifizierung 2278 Personen im Weaning betreuten, im Median pro Einrichtung 134 (Bereich [Min-Max] 44–414). Nur selten war das Weaning nicht erfolgreich, sodass vor Entlassung auf eine Heimbeatmung eingestellt werden musste (invasive Heimbeatmung Median pro Einrichtung 10 Personen, Bereich 2–25; nichtinvasive Heimbeatmung Median 0 Personen, Bereich 0–57). Festgestellt wurde ein hohes Maß an Prozess- und Strukturqualität in den zertifizierten Zentren: Über alle Prüfbereiche hinweg waren die Prüfkriterien zu allermeist erfüllt (Median Erfüllungsgrad 86 %) bzw. erfüllt mit von den Auditor*innen dokumentierten Verbesserungspotenzialhinweisen (Median 11 %). Schlussfolgerung Erfolgreiches Weaning in der NNFR und ein hohes Maß an Prozess- und Strukturqualität lassen sich anhand der Zertifizierungsergebnisse der Zentren belegen, die diesen integrativen Ansatz bei der Beatmungsentwöhnung verfolgen.

Objective: The instrument THERapy-related InterACTion (THER-I-ACT) was developed to document therapeutic interactions comprehensively in the human therapist–patient setting. Here, we investigate whether the instrument can also reliably be used to characterise therapeutic interactions when a digital system with a humanoid robot as a therapeutic assistant is used. Methods: Participants and therapy: Seventeen stroke survivors receiving arm rehabilitation (i.e., arm basis training (ABT) for moderate-to-severe arm paresis [n = 9] or arm ability training (AAT) for mild arm paresis [n = 8]) using the digital therapy system E-BRAiN over a course of nine sessions. Analysis of the therapeutic interaction: A total of 34 therapy sessions were videotaped. All therapeutic interactions provided by the humanoid robot during the first and the last (9th) session of daily training were documented both in terms of their frequency and time used for that type of interaction using THER-I-ACT. Any additional therapeutic interaction spontaneously given by the supervising staff or a human helper providing physical assistance (ABT only) was also documented. All ratings were performed by two trained independent raters. Statistical analyses: Intraclass correlation coefficients (ICCs) were calculated for the frequency of occurrence and time used for each category of interaction observed. Results: Therapeutic interactions could comprehensively be documented and were observed across the dimensions provision of information, feedback, and bond-related interactions. ICCs for therapeutic interaction category assessments from 34 therapy sessions by two independent raters were high (ICC ≥0.90) for almost all categories of the therapeutic interaction observed, both for the occurrence frequency and time used for categories of therapeutic interactions, and both for the therapeutic interaction performed by the robot and, even though much less frequently observed, additional spontaneous therapeutic interactions by the supervisory staff and a helper being present. The ICC was similarly high for an overall subjective rating of the concentration and engagement of patients (0.87). Conclusion: Therapeutic interactions can comprehensively and reliably be documented by trained raters using the instrument THER-I-ACT not only in the traditional patient–therapist setting, as previously shown, but also in a digital therapy setting with a humanoid robot as the therapeutic agent and for more complex therapeutic settings with more than one therapeutic agent being present.

Background Person-Centered-Care (PCC) requires knowledge about patient preferences. Among People-living-with-Dementia (PlwD) data on quantitative, choice-based preferences, which would allow to quantify, weigh and rank patient-relevant elements of dementia-care, and identify most/least preferred choices, are limited. The Analytic-Hierarchy-Process (AHP) may be one approach to elicit quantitative, choice-based preferences with PlwD, due to simple pairwise comparisons of individual criteria from a complex decision-problem, e.g. health care decisions. Furthermore, data on congruence of patient preferences with physicians’ judgements for PCC are missing. If patient preferences and physicians’ judgements differ, provision of PCC becomes unlikely. An understanding of patient preferences compared to physician’s judgements will support the implementation of truly PCC, i.e. state of the art dementia-care aligned with patient preferences. Methods This mixed-methods-study will be based on the results from a previous systematic review and conducted in three phases: (I) literature-based key intervention-categories of PCC will be investigated during qualitative interviews with Dementia-Care-Managers (DCMs) and PlwD to identify actually patient-relevant (sub) criteria of PCC; (II) based on findings from phase I, an AHP-survey will be designed and pre-tested for face- and content-validity, and consistency during face-to-face “thinking-aloud”-interviews with PlwD and two expert panels (DCMs and physicians); (III) the developed survey will elicit patient preferences and physicians’ judgements for PCC. To assess individual importance weights for (sub) criteria in both groups, the Principal-Eigenvector-Method will be applied. Weights will be aggregated per group by Aggregation-of-Individual-Priorities-mode. Descriptive and interferential statistical analyses will be conducted to assess congruence of importance-weights between groups. Subgroup-analyses shall investigate participant-heterogeneities, sensitivity of AHP-results shall be tested by inclusion/exclusion of inconsistent respondents. Discussion Little research is published on quantitative, choice-based preferences in dementia care. We expect that (1) PlwD have preferences and can express these, (2) that the AHP is a suitable technique to elicit quantitative, choice-based preferences among PlwD, and (3) to identify a divergence between patient preferences and physicians’ judgements for PCC. With the help of the AHP-technique, which supports systematic decision-making including multiple criteria, it may be possible to involve PlwD in future care decisions (patient participation) and ensure implementation of truly Person-Centered-Dementia-Care. Trial registration Approval of the study was granted by the Ethics Committee at the University Medicine Greifswald the 09Apr2021 (Reg.-Nr.: BB 018–21, BB 018-21a, BB 018-21b).

The B-cell CLL/lymphoma 11B gene (BCL11B) plays a crucial role in T-cell development, but its role in T-cell malignancies is still unclear. To study its role in the development of T-cell neoplasms, we generated an inducible BCL11B knockout in a murine T cell leukemia/lymphoma model. Mice, bearing human oncogenes TAL BHLH Transcription Factor 1 (TAL1; SCL) or LIM Domain Only 1 (LMO1), responsible for T-cell acute lymphoblastic leukemia (T-ALL) development, were crossed with BCL11B floxed and with CRE-ER/lox mice. The mice with a single oncogene BCL11Bflox/floxCREtg/tgTAL1tg or BCL11Bflox/floxCREtg/tgLMO1tg were healthy, bred normally, and were used to maintain the mice in culture. When crossed with each other, >90% of the double transgenic mice BCL11Bflox/floxCREtg/tgTAL1tgLMO1tg, within 3 to 6 months after birth, spontaneously developed T-cell leukemia/lymphoma. Upon administration of synthetic estrogen (tamoxifen), which binds to the estrogen receptor and activates the Cre recombinase, the BCL11B gene was knocked out by excision of its fourth exon from the genome. The mouse model of inducible BCL11B knockout we generated can be used to study the role of this gene in cancer development and the potential therapeutic effect of BCL11B inhibition in T-cell leukemia and lymphoma.

Abstract An increased low-energy positron flux is obtained from the reactor based NEPOMUC source when using its primary beam at energies as low as 20 eV. First experiments with this beam in a supported magnetic dipole trap resulted in the maximum current of injected positrons to date. According to single-particle simulations, remaining limitations in the injection efficiency, observed in the experiment, can be attributed to the spatial spread of the beam. In the first trapping measurements with this beam, top-down asymmetries in the electrostatic trapping potential are found to be detrimental to confinement.